The value of referring to recently introduced antipsychotics as "second generation"

被引：13

作者：

Lohr, JB ^{[1
]}

Braff, DL ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA

来源：

AMERICAN JOURNAL OF PSYCHIATRY | 2003年 / 160卷 / 08期

关键词：

D O I：

10.1176/appi.ajp.160.8.1371

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

引用

页码：1371 / 1372

页数：2

共 8 条

[1] Tardive dyskinesia and atypical antipsychotic drugs [J].

Casey, DE .

SCHIZOPHRENIA RESEARCH, 1999, 35 :S61-S66

[2] Current and emerging second-generation triptans in acute migraine therapy: A comparative review [J].

Deleu, D ;

Hanssens, Y .

JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (07) :687-700

[3]

Feltus M S, 1999, Can J Clin Pharmacol, V6, P187

[4] Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? [J].

Green, MF ;

Kern, RS ;

Braff, DL ;

Mintz, J .

SCHIZOPHRENIA BULLETIN, 2000, 26 (01) :119-136

[5] Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications [J].

Green, MF ;

Braff, DL .

BIOLOGICAL PSYCHIATRY, 2001, 49 (04) :374-384

[6] THE EVOLUTION OF THE SEROTONIN-DOPAMINE ANTAGONIST CONCEPT [J].

HUTTUNEN, M .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (01) :S4-S10

[7]

Möller HJ, 1999, EUR ARCH PSY CLIN N, V249, P99

[8] Risperidone versus clozapine in treatment-resistant schizophrenia:: A randomized pilot study [J].

Wahlbeck, K ;

Cheine, M ;

Tuisku, K ;

Ahokas, A ;

Joffe, G ;

Rimón, R .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2000, 24 (06) :911-922

← 1 →